Stock Analysis
- Hong Kong
- /
- Healthcare Services
- /
- SEHK:9860
Top SEHK Growth Companies With High Insider Ownership In July 2024
Reviewed by Simply Wall St
As global markets navigate through varying economic signals, Hong Kong's market has shown resilience amidst a backdrop of international uncertainties. In this context, growth companies with high insider ownership in Hong Kong stand out as potentially robust investment opportunities due to the alignment of management’s interests with shareholders, particularly during turbulent times.
Top 10 Growth Companies With High Insider Ownership In Hong Kong
Name | Insider Ownership | Earnings Growth |
iDreamSky Technology Holdings (SEHK:1119) | 20.2% | 104.1% |
Fenbi (SEHK:2469) | 32.6% | 43% |
Adicon Holdings (SEHK:9860) | 22.4% | 28.3% |
Tian Tu Capital (SEHK:1973) | 34% | 70.5% |
DPC Dash (SEHK:1405) | 38.2% | 90.2% |
Zylox-Tonbridge Medical Technology (SEHK:2190) | 18.7% | 79.3% |
Zhejiang Leapmotor Technology (SEHK:9863) | 15% | 76.5% |
Beijing Airdoc Technology (SEHK:2251) | 28.7% | 83.9% |
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 13.9% | 100.1% |
Ocumension Therapeutics (SEHK:1477) | 23.1% | 93.7% |
We're going to check out a few of the best picks from our screener tool.
China Ruyi Holdings (SEHK:136)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: China Ruyi Holdings Limited operates as an investment holding company focused on content production and online streaming, serving markets in the People's Republic of China, Hong Kong, Europe, and internationally, with a market capitalization of HK$26.26 billion.
Operations: The company generates revenue primarily through its content production business, which brought in CN¥2.23 billion, and its online streaming and gaming segments, which together accounted for CN¥1.38 billion.
Insider Ownership: 15.1%
Earnings Growth Forecast: 14.7% p.a.
China Ruyi Holdings, with a forecasted annual revenue growth of 27.7%, is outpacing the Hong Kong market average. However, its profit margins have declined from 59.8% to 19% over the past year, reflecting challenges despite high insider ownership. The company recently raised HK$4 billion through an equity offering and amended its bylaws, signaling active strategic adjustments. Despite substantial share dilution last year, it trades at a significant discount to estimated fair value, suggesting potential undervaluation amidst operational shifts.
- Take a closer look at China Ruyi Holdings' potential here in our earnings growth report.
- The analysis detailed in our China Ruyi Holdings valuation report hints at an inflated share price compared to its estimated value.
Beijing Fourth Paradigm Technology (SEHK:6682)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Beijing Fourth Paradigm Technology Co., Ltd. is an investment holding company that offers platform-centric artificial intelligence solutions in the People's Republic of China, with a market capitalization of approximately HK$24.91 billion.
Operations: The company generates revenue through three primary segments: the Sage AI Platform (CN¥2.51 billion), SageGPT AIGS Services (CN¥0.42 billion), and Shift Intelligent Solutions (CN¥1.28 billion).
Insider Ownership: 22.8%
Earnings Growth Forecast: 96% p.a.
Beijing Fourth Paradigm Technology is poised for significant growth, with revenue expected to increase by 19.3% annually, outstripping the Hong Kong market's 7.8%. However, its Return on Equity is projected at a modest 6% in three years. Recent leadership changes, including the promotion of Mr. Yu to vice chairman and Ms. Guo's appointment as acting CFO, underscore strategic shifts aimed at bolstering operations and sustainable development. The company also initiated a share repurchase program, enhancing shareholder value.
- Get an in-depth perspective on Beijing Fourth Paradigm Technology's performance by reading our analyst estimates report here.
- The valuation report we've compiled suggests that Beijing Fourth Paradigm Technology's current price could be inflated.
Adicon Holdings (SEHK:9860)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Adicon Holdings Limited, with a market cap of HK$7.40 billion, operates medical laboratories across the People’s Republic of China.
Operations: The company generates revenue primarily from its healthcare facilities and services segment, totaling CN¥3.30 billion.
Insider Ownership: 22.4%
Earnings Growth Forecast: 28.3% p.a.
Adicon Holdings, a growth-oriented firm in Hong Kong with high insider ownership, has initiated a substantial share repurchase program, signaling strong future confidence. Despite this positive move, the company's profit margins have decreased from last year to 7.1%. However, earnings are expected to grow significantly at 28.3% annually over the next three years, outperforming the broader Hong Kong market's forecast of 11.3%. Additionally, revenue growth is projected to exceed local market trends at 15.1% annually.
- Dive into the specifics of Adicon Holdings here with our thorough growth forecast report.
- Upon reviewing our latest valuation report, Adicon Holdings' share price might be too optimistic.
Next Steps
- Click this link to deep-dive into the 54 companies within our Fast Growing SEHK Companies With High Insider Ownership screener.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're helping make it simple.
Find out whether Adicon Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SEHK:9860
Adicon Holdings
Operates medical laboratories in the People’s Republic of China.